In the past year, advances in genome editing with CRISPR and immunotherapy have accelerated the pace of discovery of novel constructs to win the war against cancer. The armamentarium of tools has resulted in rapid progress in the advancement of new therapies to the clinic, but a major bottleneck remains the discovery and validation of novel targets. The Novel Targets for Cancer and Emerging Therapeutic Areas conference at PEGS Europe will look at innovative approaches to uncover and vet novel targets that can lead to first-in-class medicines in oncology and beyond.
DISCOVERING DISEASE-ASSOCIATED EPITOPES AND PATIENT-DERIVED APPROACHES
Using Phage Display of Antibodies as a Discovery Tool to Identify Disease-Related Targets
Peter Kristensen, PhD, Head of Section of Biotechnology, Associate Professor, Department of Chemistry and Bioscience, Aalborg University
Microsphere Affinity Proteomics: High Throughput Deconvolution of Antibody Libraries
Fridtjof Lund-Johansen, MD, PhD, Senior Scientist, Department of Immunology, Oslo University Hospital
Targeting Early Changes in the Synovial Microenvironment: A New Class of Immunomodulatory Therapy?
Kim Midwood, Professor at Kennedy Institute of Rheumatology, University of Oxford
B CELL-DERIVED ANTIBODIES FROM TUMOURS
BCR-Dependent Lineage Plasticity in Mature B Cells
Robin Graf, Dr. rer. nat., Immune Regulation and Cancer, Max Delbrück Center for Molecular Medicine in the Helmholtz Association
Targeting LILRB4 for Cancer Therapy
Zhiqiang An, PhD, Professor and Robert A. Welch Distinguished University Chair, Chemistry, Brown Foundation Institute of Molecular Medicine, Director, Texas Therapeutics Institute, University of Texas Health Science Center, Houston
Antibody Discovery for Metabolic Enzyme and Immuno-Oncology Targets
Maria Groves, PhD, Associate Director, Lab Head for the CRUK/Medimmune Alliance, AstraZeneca
CHALLENGES AHEAD FOR CANCER IMMUNOTHERAPY/IMMUNE PHENOTYPES
A New Era in Cancer Therapeutics: Biologic Problems and Engineering Solutions
Daniel Chen, MD, PhD, CMO, IGM Biosciences
Avidity-Based Binding to HER2 Results in Selective Killing of HER2 Over-Expressing Cells by Anti-HER2/CD3
Teemu Juntilla, PhD, Senior Scientist, Translational Oncology, Genentech
NEXT GENERATION APPROACHES (ANTIBODY-BASED)
Engineered IgM-Based Antibodies
Bruce Keyt, PhD, CSO, IGM Biosciences
Novel Antibody Engineering to Improve Therapeutic Index of Antibody Targeting Solid Tumors
Kanako Tatsumi, PhD, Researcher, Discovery Biologics, Chugai Pharmaceutical Co., Ltd.
* The program is subject to change without notice, due to unforeseen reason.